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Hyperspectral system imaging for detection
of cancer cells
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In recent years, hyperspectral system imaging (HSI) has been
used as a tool for the detection of nanomaterials in biological
matrices. Here we present using the HSI for obtaining of hyper-
spectral images in a complex and highly dispersive environment,
such as cell cultures. This information is necessary to develop an
effective strategy for the detection of cancer cells. HSI records the
scattering of light in the visible and near-infrared (VNIR, 400–
1000 nm) regions in each pixel of the image field. Using the HSI it
is possible to find out the spectral profile that is unique to the each
studied object. We studied human colon carcinoma (HCT-116)
and human prostate adenocarcinoma (PC3) cell lines. Thus, we
collected a scattering intensity database that provided the spectra
of cancer cells. The spectral profile for HCT-116 showed a bi-
modal peak at 550 nm and 675 nm. For PC3, the spectrum showed
a band with a maximum at 600 nm and with a noticeable shoulder
at 675 nm. The spectral profile for different cancer cells is sig-
nificantly different, that allows for optical and spectral differen-
tiation. The work was done at the expense of subsidies allocated
as part of the state support of KFU in order to increase its com-
petitiveness among the world’s leading scientific and educational
centers, and through funding under the state 16.2822.2017/4.6 and
MD-6655.2018.4. Also, the work was partially carried out with
the financial support of the Russian Foundation for Basic Re-
search and the government of the RT grant 18-44-160001.
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Induction of cell death in human melanoma cell
lines by the combination of p14ARF plus
interferon-b gene transfer
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In our cancer immunotherapy approach, we aim to induce both
cell death and an anti-tumour immune response upon gene transfer.
Previously, we have shown that combined p19Arf (functional
partner of p53) and interferon-b (IFNb, pleiotropic cytokine) gene
transfer resulted in elevated levels of cell killing associated with
markers necroptosis, immunogenic cell death (ICD) and immune
activation in a mouse model of melanoma. Here we present a critical
advance in our understanding of how this approach impacts human
melanoma cells. We have constructed non-replicating Ad5 vectors
with constitutive expression of either human p14ARF or IFNb and
applied these viruses to the UACC62 and SK-Mel-29 cell lines. For
both, elevated levels of killing were encountered upon combined
gene transfer as compared to single gene treatment as measured by
the accumulation of hypodiploid cells, activation of caspases 3/7
and annexin-V staining. Strikingly, pan-caspase inhibition using Z-
VAD-FMK peptide blocked cell death in UACC62, but not SK-
Mel-29, indicating a non-apoptotic mechanism of cell death in the
latter case. In situ gene therapy of s.c. UACC62 tumours in nude
mice revealed superior inhibition of progression when four doses of
combined gene therapy were applied, an effect that could be ex-
tended with additional virus injections. While combined p14AR-
F+IFNb gene transfer is beneficial for cell killing and control of
tumour progression, much remains to be studied with regard to the
mechanism of cell death and immune activation in response to our
gene therapy approach in human cells. Supported by the Sao Paulo
Research Foundation (FAPESP), CNPQ and CAPES.
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Antitumor properties of artificial microvesicles
from mesenchymal stem cells overexpressing
TNF-related apoptosis inducing ligand
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Almost all human cells release extracellular vesicles (EVs),
spherical micro- and nanoparticles, which are separated from the
cell surface and participate in intercellular communication. EVs are
a promising tool for the delivery of bioactive molecules for thera-
peutic purposes. One of the promising cytokines with anti-cancer
properties is TNF-related apoptosis-inducing ligand (TRAIL) which
is able to selectively induce apoptosis in malignant but not normal
cells. The ideal cell type for the production of EVs is human mes-
enchymal stem cells (MSCs) as they exhibit a homing behaviour to
tumor niches and MSC-isolated EVs retain the ability of the parental
cells to migrate toward tumor sites. Genetic modification of MSCs
with TRAIL gene and the subsequent production of EVs from them
can be a promising approach for cancer treatment. This study was
performed in the accordance with approved ethical standards and
current legislation (protocol approved by the Committee on Bio-
medical Ethics of KFU (No.3, 03/23/2017)) and supported by grant
MK-236.2019.4. In this study, MSCs with TRAIL overexpression
were treated with cytochalasin B to increase the yield of EVs. Cy-
tochalasin B-induced artificial microvesicles (CIMVs-TRAIL)
were positive for CD44, CD90 and CD105 MSC surface markers,
but CD29 and CD73 expression was significantly decreased (about
10%). TRAIL expression in CIMVs was confirmed by qPCR and
Western blot. Using TEM and flow cytometry CIMVs-TRAIL were
shown to be mostly 50–200 nm in diameter which is comparable
with natural EVs. CIMVs-TRAIL exhibited significant antitumor
activity in SH-SY5Y tumor cells culture in vitro.
P151
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The transformational impact of bioorthogonal chemistries has
inspired new strategies for the in vivo synthesis of bioactive agents
































































have played a prominent role in the growing subfield of bioortho-
gonal catalysis by producing xenobiotics and uncaging biomolecules
in living systems, and new exciting Pdcatalyzed reactions and ap-
plications continue to emerge. However, delivering catalysts selec-
tively to specific cell types still lags behind catalyst development.
Towards this goal, we have developed a bio-artificial device con-
sisting of cancer-derived exosomes loaded with Pd catalysts by a
novel method that enables the controlled assembly of Pd nanosheets
directly inside the vesicles. This new hybrid system mediates Pd-
triggered dealkylation reactions in vitro and inside cells and displays
preferential tropism for their progenitor cells. The use of Trojan
exosomes to deliver abiotic catalysts into designated cancer cells
creates the opportunity for a new targeted therapy modality:
exosome-directed catalyst prodrug therapy, whose first steps are
presented herein with the cell-specific release of the recently ap-
proved anticancer drug panobinostat.
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WEE1 and CHK1 gene silencing using Polypurine
Reverse Hoogsteen Hairpins
E Aubets1 C J Ciudad1 V Noé1
1: University of Barcelona
We investigated the inhibition of CHK1 and WEE1 genes, using
Polypurine Reverse Hoogsteen hairpins (PPRHs). PPRHs are gene
silencing molecules, composed by two mirror repeat polypurine
domains, linked by a pentathymidine loop and bound by in-
tramolecular reverse-Hoogsteen bonds. Different PPRHs were de-
signed, 3 directed to WEE1 and 4 to CHK1. All PPRHs were tested
individually at 100 nM in HeLa cells in cell viability assays. Five
PPRHs reduced cell viability around 80% and were tested in PC3
cell line with similar results. We observed a dose-dependent ef-
fect in reducing cell viability when using HpWEE1Pr-T and
HpCHK1I1-C. In addition, time-course assays, showed that
HpWEE1Pr-T and HpCHK1I1-C were cytotoxic with only 6 hours
of cell incubation at 100 nM. After 20 hours of incubation with
HpCHK1I1-C and HpWEE1Pr-T, there was an increase in apo-
ptotic cell population of 3-fold. The treatment of HpWEE1Pr and
HpCHK1I1-C reduced mRNA levels of their target genes between
1.6-2-fold. Moreover, we observed a decrease of 50% WEE1 pro-
tein levels after 24 h incubation of HpWEE1Pr-T and a decrease of
50% of CHK1 protein levels after 15 h of incubation of HpCHK1I1-
C. In addition, we observed the formation of two splice variants of
CHK1 mRNA after 24 h of incubation with HpCHKI1I1-C. In
conclusion, Inhibition of WEE1 and CHK1 genes using PPRHs
results in decreases in mRNA and protein levels and increases in
apoptosis. Moreover, HpCHK1I1-C promotes the appearance of
new splicing variants. Thus, PPRHs can be used to inhibit genes
involved in replicative stress as anti-cancer gene therapy.
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Production of mouse mesenchymal stem cell lines
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Mesenchymal stem cells (MSCs) are a major component of the
tumor microenvironment and play a key role in promoting tumor
progression. MSCs have been shown to exhibit a homing behavior
toward tumor sites that makes it perspective vehicles for anti-
cancer agent delivery, particularly chemotherapy drugs. The
ffLuc-encoding gene cloned from the Photinus pyralis is the most
studied and well characterized bioluminescent reporter gene. In
this study mouse MSCs (mMSCs) that express the luciferase re-
porter gene (ffLuc) or Katushka2S were produced. mMSCs were
isolated by enzymatic digestion with collagenase. This study was
performed in the accordance with approved ethical standards and
current legislation (the protocol was approved by the Committee
on Biomedical Ethics of KFU (No. 3, 03/23/2017)) and with
support by RFBR grant 18-34-00738. The cells were largely
positive for MSC surface markers (CD44, CD90, CD29, CD105,
CD73 and Sca-1) and negative for hematopoietic stem cell
markers. Recombinant lentiviruses LV-ffLuc and LV-Katushka2S
were produced by co-transfection of the HEK293T packing cell
line. The viral titer was determined by flow cytometry of cells
transfected with lentiviruses carrying Katushka2S. mMSCs were
transduced with recombinant lentiviral vectors encoding ffLuc or
Katushka2S gene. Resulting mMSCs-ffLuc cell line was selected
with puromycin for 10 days. The relative intensity and stability of
the firefly luciferase signal in mMSCs-ffLuc were analyzed by
using ONE-Glo Luciferase Assay System. Obtained mMSCs-
ffLuc cell line with a stable luminescent signal will be further
primed with various chemotherapeutic drugs and its antitumor
properties will be analyzed in vitro.
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Replicating retroviral vectors spread on the human
retinoblastoma SNUOT-Rb1 cells and induce cell
death
S Kim1 T M Bui1 Y Lee1 Y Kim1 M Kang1 Y -S Kim1
1: Chungnam National University
A couple of viruses have been developed as oncolytic vir-
otherapy to kill infected tumor cells directly. However, a
couple of problems of oncolytic virotherapy such as early viral
clearance by host immune system and frequent attenuation
of the viral infectivity raised the need of new tools for vir-
otherapy. As a promising tool for cancer treatment, replicating
retroviral vector (RRV) is known to have high selectivity into
tumors and stability in gene transfer because RRV can repli-
cate only in dividing cells and has extremely low immunoge-
nicity. Retroviral-mediated transfer of the herpes simplex virus
type 1 thymidine kinase (HSV1-TK) gene or yeast cytosine
deaminase (yCD) gene into glioma followed by treatment with
prodrug has been widely used for glioma gene therapy clinical
trials. One of the most common childhood cancer, Retino-
blastoma (Rb), is an intraocular tumor that grows rapidly and
poses a threat to sight and life. In this study, we examined the
potential of a split-RRV system encoding HSV1-TK and yCD
gene for retinoblastoma gene therapy. We, here, show the
feasibility of RRV for retinoblastoma gene therapy.
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Development of lipid nanoparticles for the mRNA-
mediated cancer immunotherapy
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